Published in J Infect Dis on December 14, 2005
Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn (2008) 1.82
Epstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer (2014) 1.32
The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res (2009) 1.31
Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. J Virol (2009) 1.03
Epstein-barr virus sequence variation-biology and disease. Pathogens (2012) 0.95
Genome-wide analysis of wild-type Epstein-Barr virus genomes derived from healthy individuals of the 1,000 Genomes Project. Genome Biol Evol (2014) 0.89
Validation of Roche LightCycler Epstein-Barr virus quantification reagents in a clinical laboratory setting. J Mol Diagn (2006) 0.85
EBNA1 and LMP1 variants in multiple sclerosis cases and controls. Acta Neurol Scand (2010) 0.83
Epstein-Barr virus genetic variants are associated with multiple sclerosis. Neurology (2015) 0.83
Epstein-Barr virus latent membrane protein 1 genetic variability in peripheral blood B cells and oropharyngeal fluids. J Virol (2014) 0.80
Role for HLA in susceptibility to infectious mononucleosis. J Clin Invest (2007) 0.80
Geographic Population Structure in Epstein-Barr Virus Revealed by Comparative Genomics. Genome Biol Evol (2016) 0.76
A novel recombinant variant of latent membrane protein 1 from Epstein Barr virus in Argentina denotes phylogeographical association. PLoS One (2017) 0.76
Distribution, persistence and interchange of Epstein-Barr virus strains among PBMC, plasma and saliva of primary infection subjects. PLoS One (2015) 0.75
Identification of functional elements and regulatory circuits by Drosophila modENCODE. Science (2010) 12.39
Discovery of functional elements in 12 Drosophila genomes using evolutionary signatures. Nature (2007) 11.66
Epstein-Barr virus: 40 years on. Nat Rev Cancer (2004) 9.70
Comparative functional genomics of the fission yeasts. Science (2011) 6.00
Reliable prediction of regulator targets using 12 Drosophila genomes. Genome Res (2007) 4.89
Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog (2006) 4.80
Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Anal Chem (2003) 4.72
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol (2007) 4.14
Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int (2009) 2.99
Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med (2002) 2.89
Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature (2003) 2.77
Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol (2004) 2.55
Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol Cell (2012) 2.54
Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci U S A (2010) 2.34
Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol (2004) 2.20
Microvesicles and viral infection. J Virol (2011) 2.10
Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med (2003) 2.01
A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J Immunol (2006) 1.98
Measuring coverage in MNCH: a prospective validation study in Pakistan and Bangladesh on measuring correct treatment of childhood pneumonia. PLoS Med (2013) 1.90
Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst (2004) 1.80
Characterization of differentiated quiescent and nonquiescent cells in yeast stationary-phase cultures. Mol Biol Cell (2008) 1.75
Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood (2010) 1.75
Increased expression of the NK cell receptor KLRG1 by virus-specific CD8 T cells during persistent antigen stimulation. J Virol (2005) 1.74
Genomic analysis of stationary-phase and exit in Saccharomyces cerevisiae: gene expression and identification of novel essential genes. Mol Biol Cell (2004) 1.72
A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med (2007) 1.70
EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol (2003) 1.70
Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet (2003) 1.70
Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J Mol Diagn (2004) 1.64
CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med (2005) 1.61
Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol (2006) 1.61
Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res (2003) 1.60
Quantifying reproducibility for differential proteomics: noise analysis for protein liquid chromatography-mass spectrometry of human serum. Bioinformatics (2004) 1.57
An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog (2009) 1.56
Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res (2002) 1.53
Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. J Virol (2008) 1.51
Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K. Oncogene (2005) 1.47
CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1. J Exp Med (2004) 1.47
Predictive regulatory models in Drosophila melanogaster by integrative inference of transcriptional networks. Genome Res (2012) 1.47
EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog (2007) 1.46
The Epstein-Barr Virus BART microRNAs target the pro-apoptotic protein Bim. Virology (2011) 1.45
Compartmentalization and transmission of multiple epstein-barr virus strains in asymptomatic carriers. J Virol (2003) 1.45
Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res (2004) 1.37
LMP1 strain variants: biological and molecular properties. J Virol (2006) 1.35
Potential selection of LMP1 variants in nasopharyngeal carcinoma. J Virol (2004) 1.34
New algorithms for processing and peak detection in liquid chromatography/mass spectrometry data. Rapid Commun Mass Spectrom (2002) 1.34
Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J Virol (2009) 1.31
Immune defence against EBV and EBV-associated disease. Curr Opin Immunol (2011) 1.31
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev (2014) 1.30
Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta. J Virol (2011) 1.28
Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol (2011) 1.27
Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci U S A (2006) 1.26
Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance. J Clin Invest (2005) 1.26
Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J Virol (2004) 1.25
T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol (2007) 1.23
Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res (2002) 1.22
Epstein-Barr Virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn Mol Pathol (2004) 1.22
The proteomics of quiescent and nonquiescent cell differentiation in yeast stationary-phase cultures. Mol Biol Cell (2011) 1.21
Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proc Natl Acad Sci U S A (2010) 1.20
I-mfa domain proteins interact with Axin and affect its regulation of the Wnt and c-Jun N-terminal kinase signaling pathways. Mol Cell Biol (2002) 1.20
Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling. J Virol (2005) 1.19
Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow. Blood (2008) 1.19
EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration. Cancer Res (2008) 1.19
Infection of Epstein-Barr virus in a gastric carcinoma cell line induces anchorage independence and global changes in gene expression. Proc Natl Acad Sci U S A (2012) 1.18
Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program (2007) 1.17
Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J Immunol (2009) 1.17
Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol (2009) 1.16
Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer (2002) 1.15
Modulation of B-cell exosome proteins by gamma herpesvirus infection. Proc Natl Acad Sci U S A (2013) 1.14
Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood (2002) 1.13
Accumulation of cytoplasmic beta-catenin and nuclear glycogen synthase kinase 3beta in Epstein-Barr virus-infected cells. J Virol (2004) 1.13
Unique signaling properties of CTAR1 in LMP1-mediated transformation. J Virol (2007) 1.12
Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog (2009) 1.11
The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children. J Infect Dis (2009) 1.09
Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3. J Virol (2008) 1.09
B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood (2002) 1.08
EBV-associated mononucleosis leads to long-term global deficit in T-cell responsiveness to IL-15. Blood (2006) 1.06
The role of miRNAs and EBV BARTs in NPC. Semin Cancer Biol (2011) 1.06
Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood (2008) 1.05
Evolutionary principles of modular gene regulation in yeasts. Elife (2013) 1.05
Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity. J Virol (2005) 1.05
Alterations of the characteristics of the circadian rest-activity rhythm of cancer in-patients. Chronobiol Int (2007) 1.03
New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer. J Natl Cancer Inst (2002) 1.03
Expression profile of microRNAs in Epstein-Barr virus-infected AGS gastric carcinoma cells. J Virol (2013) 1.02
Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition. J Immunol (2011) 1.02
MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc Natl Acad Sci U S A (2002) 1.01
The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol (2015) 1.00
Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice. PLoS Pathog (2012) 1.00
Epstein-Barr virus colonization of tonsillar and peripheral blood B-cell subsets in primary infection and persistence. Blood (2009) 1.00
TRAF interactions with raft-like buoyant complexes, better than TRAF rates of degradation, differentiate signaling by CD40 and EBV latent membrane protein 1. Int J Cancer (2005) 1.00
EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. J Immunol (2008) 0.99
Release of extraction-resistant mRNA in stationary phase Saccharomyces cerevisiae produces a massive increase in transcript abundance in response to stress. Genome Biol (2006) 0.98
The need and challenges for development of an Epstein-Barr virus vaccine. Vaccine (2013) 0.98
Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res (2013) 0.97